Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

12.16 -1.80 (-12.86%)
Streaming Delayed Price Updated: 3:02 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptive Biotechnologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Earnings Scheduled For February 11, 2025 ↗
 
Via Benzinga
News headline image
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance ↗
The company expects sales to grow 12% to 13% annually in the long term. 
Via Investor's Business Daily
News headline image
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025 ↗
Cathie Wood-led Ark Invest sold 140,518 shares of Palantir and bought shares of Tempus AI Inc. The total value of the trades is about $9.1 million. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce ↗
Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT. 
Via Benzinga
Topics Workforce
News headline image
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Two Big Weeks To Play A Rally In Biotech And Healthcare Stocks ↗
The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks That May Collapse This Quarter ↗
 
Via Benzinga
News headline image
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Smaller Cap Biotechs Are In Season: How Are We Doing? ↗
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
News headline image
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500 ↗
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
News headline image
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Jabil Posts Upbeat Earnings, Joins Micron Technology, Southwest Airlines And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Down Over 2%; US Initial Jobless Claims Fall ↗
 
Via Benzinga
News headline image
A Biotech Breakout Will Be Led By Small Caps ↗
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever. 
Via Talk Markets
Topics Artificial Intelligence Economy
News headline image
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
3 Precision Medicine Stocks Tailoring Treatments ↗
With technological developments pushing the boundaries of healthcare, these are the precision medicine stocks to consider. 
Via InvestorPlace
News headline image
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Trading SMID Biotech Stocks In A Volatile Market ↗
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.